Nadmed

Executive Summary

Nadmed Ltd is a Finnish biotechnology company founded in 2019, specializing in the precise measurement of nicotinamide adenine dinucleotide (NAD) metabolites and glutathione. The company offers CE-marked blood testing kits and laboratory services, positioning itself as the gold standard for accurate, rapid, and cost-effective NAD quantification. Its technology targets clinical diagnostics and research in metabolism, aging, and mitochondrial health, addressing a growing demand for biomarkers in longevity and metabolic disorders. By providing reliable NAD measurement, Nadmed aims to enable personalized health interventions and advance understanding of cellular energy dynamics. Currently in the pre-clinical stage, Nadmed operates as a private company with no disclosed funding or valuation. Its CE-marked products allow it to serve the European market, but scalability and adoption remain limited. Key risks include competition from larger diagnostic firms, regulatory hurdles for expansion, and reliance on niche research interest. However, the company's differentiated focus on NAD metabolites, a crucial biological cofactor, positions it well for partnerships with research institutions and pharmaceutical companies exploring anti-aging therapies. Nadmed's near-term success hinges on securing funding for commercialization and establishing collaborative agreements to validate its technology in clinical settings.

Upcoming Catalysts (preview)

• Q3 2026Series A funding round to scale commercial operations60% success
• Q4 2026Strategic partnership with a longevity-focused research institute50% success
• Q2 2026Expansion of CE-marked test menu to include additional metabolites70% success